Specialty Tiers Hinder Access for ACA Exchange Patients
Patients who had hoped to attain comprehensive health care coverage through the Affordable Care Act may be discovering yet another roadblock to treatment.
More States Make the Grade on Pain Policy
State by state, the U.S. is enacting better health policy on the issue of pain management.
Shift to OTC Medications Could Improve Patient Access
Claritin, Zantac, the nicotine patch – even children’s Advil – were once accessible only by prescription.
“21st Century Cures” Require Improved Trials Process
Innovation, data sharing and public-private partnerships could help modernize clinical trials, agreed witnesses at Wednesday’s “21st Century Cures” hearing by the House Energy and Commerce Committee Health Subcommittee.
The Compassion Question
Should seriously ill patients who are running out of time – and have exhausted available medical treatments – have the right to try drugs not yet approved by the FDA?
NY Legislators Embrace Abuse-Deterrent Technology
Legislators in the New York State Senate have made a bold move. Amid mounting concern about pain pill abuse, state senators passed Bill 7125, requiring New York pharmacists to dispense abuse-deterrent formulas for opioid analgesic prescriptions.
Limited Networks May Limit Options for Rare Disease Patients
Limiting health care provider networks may save money for insurers grappling with the Affordable Care Act.
Panel Makes Case for Unique Drug Names
Tracking and analyzing patients’ adverse reactions to medications – a process known as pharmacovigilance – is crucial to patient safety.
Cost, Quality Debates Dominate Cancer Policy Workshop
How do we go about ”Ensuring Patient Access to Cancer Drugs”? Ethicists, economists, physicians and academics gathered for the Institute of Medicine’s National Cancer Policy Forum Workshop this week to discuss the topic.
WHO Calls for Improved, Science-based Regulations on Biosimilars
Patients worldwide need access to affordable biosimilars, the World Health Organizations’ World Health Assembly (WHA) says, but not at the expense of safety or science.
